2012-11-13T12:54:31-06:00 2011-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2011-01-01 943384500 INSTITUTE FOR ONEWORLD HEALTH INST 6503922510 280 UTAH AVENUE NO 250 SAN FRANCISCO CA 94080 MARLOW KEE 6503922510 2012-11-13 1 3019519090 2011 2016-02-24 21:20:13Z X JACQUELINE SHERRIS 280 UTAH AVENUE NO 250 SAN FRANCISCO CA 94080 30773681 0 X WWW.ONEWORLDHEALTH.ORG X 2000 CA SEE PART III, LINE 1. 7 6 27 6 0 0 26173980 15708021 0 0 52248 78945 173634 0 26399862 15786966 5441466 1895400 0 0 4701962 4015023 0 0 126698 7660915 7766314 17804343 13676737 8595519 2110229 26215343 24285254 4437688 1581867 21777655 22703387 X THE INSTITUTE FOR ONE WORLD HEALTH (IOWH) IS A NONPROFIT DRUG DEVELOPMENT PROGRAM WITH A MISSION TO DISCOVER, DEVELOP, AND DELIVER SAFE, EFFECTIVE, AND AFFORDABLE NEW TREATMENTS FOR DISEASES DISPROPORTIONATELY AFFECTING PEOPLE IN THE DEVELOPING WORLD. 0 0 4534563 235400 IOWH DEVELOPS DRUGS TO TREAT SEVERE DIARRHEAL DISEASE, WHICH CAN BE FATAL, ESPECIALLY FOR YOUNG CHILDREN. ONE OF THESE DRUGS, KNOWN AS IOWH032, MAY PREVENT MASSIVE DIARRHEAL FLUID LOSS CAUSED BY DISEASES SUCH AS CHOLERA. COMBINED WITH CURRENT TREATMENTS FOR INFECTIOUS DIARRHEA, THIS DRUG IS EXPECTED TO REDUCE MORTALITY AND IMPROVE THE QUALITY OF LIFE. ACTIVITIES IN 2011 INCLUDED (1) RECEIVING US FOOD AND DRUG ADMINISTRATION APPROVAL OF AN INVESTIGATIONAL NEW DRUG APPLICATION TO PROCCED WITH PHASE 1 CLINICAL TRIALS FOR IOWH032; (2) INITIATING PHASE 1 CLINICAL TRIALS FOR IOWH032; (3) PARTNERING WITH ANACOR PHARMACEUTICALS TO DISCOVER ANTIBACTERIAL COMPOUNDS FOR TREATING BLOODY DIARRHEA CAUSED BY SHIGELLOSIS; (4) PARTNERING WITH A-CUBE TO DEVELOP DNA VACCCINES FOR OTHER DIARRHEAL DISEASES; AND (5) PARTNERING WITH THE CENTER FOR WORLD HEALTH AND MEDICINE AT ST. LOUIS UNIVERSITY TO ANNOUNCE A JOINT RESEARCH AGREEMENT TO DEVELOP NEW DRUGS TO COMBAT DIARRHEA. 2029013 15000 IOWH HAS DEVELOPED PAROMOMYCIN INTRAMUSCULAR INJECTION (PMIM) FOR TREATMENT OF VISCERAL LEISHMANIASIS, A PARASITIC DISEASE THAT IS USUALLY FATAL IF UNTREATED. IOWH HAS WORKED TO EXPAND ACCESS TO PMIM IN COUNTRIES IN WHICH THE DISEASE IS ENDEMIC. ACCOMPLISHMENTS IN 2011 INCLUDED (1) COMPLETING ENROLLMENT FOR A PMIM SAFETY/EFFICACY STUDY IN BANGLADESH; (2) ENGAGING IN A FOUR-YEAR, INTERNATIONAL COLLABORATION TO BOOST STRATEGIES TO CONTROL AND EVENTUALLY ELIMINATE VISCERAL LEISHMANIASIS IN INDIA AND BANGLADESH; AND (3) FACILITATING NEPAL'S APPROVAL OF PMIM FOR ITS ESSENTIAL DRUG LIST. 1978390 1560000 IOWH HAS COLLABORATED WITH PARTNERS TO USE SYNTHETIC BIOLOGY TECHNIQUES TO PRODUCE A HIGH-QUALITY, LOW-COST SUPPLY OF ARTEMISININ, A KEY COMPONENT OF RECOMMENDED TREATMENT FOR UNCOMPLICATED MALARIA. THIS PROJECT AIMS TO ENHANCE THE SECURITY OF ARTEMISININ SUPPLIES AND INCREASE THE AVAILABILITY OF TREATMENT TO VULNERABLE POPULATIONS. IN 2011 IOWH BEGAN THE PRODUCTION AND DISTRIBUTION PHASE OF THE SEMISYNTHETIC ARTEMISININ PROJECT IN COLLABORATION WITH SANOFI, A GLOBAL PHARMACEUTICAL COMPANY. SEMISYNTHETIC ARTEMISININ IS EXPECTED TO BE AVAILABLE TO QUALIFIED BUYERS IN 2012 OR 2013. 1347012 85000 IOWH IS CONTINUING ITS WORK TO DEVELOP TECHNICAL CAPACITY FOR THE DIAGNOSIS OF HELMINTH INFECTIONS AND CONDUCT AN EPIDEMIOLOGICAL SURVEY ON SOIL-TRANSMITTED HELMINTH INFECTIONS IN INDIA. IN 2011, IOWH PARTNERED WITH THE JHARKHAND STATE DEPARTMENT OF HEALTH TO SUPPORT A CONTROL INITIATIVE FOR SOIL-TRANSMITTED HELMINTHS.IOWH IS ALSO CONTRIBUTING TO INDIA'S POLIO ERADICATION EFFORTS. IN 2011 IOWH RECEIVED FUNDING FOR AND LAUNCHED AN ADVOCACY PROGRAM TO HELP MAINTAIN POLIO-FREE STATUS IN SELECTED STATES. 1347012 85000 9888978 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 45 0 1 27 1 0 1 IN 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X MARLOW KEE CHIEF FINANCIAL OFFICER 6503922510 2201 WESTLAKE AVENUE SUTIE 200 SEATTLE WA 98121 RICHARD CHIN 40.00 X X 795773 0 32146 JACQUELINE SHERRIS 2.00 X 0 0 0 CHRISTOPHER J ELIAS 2.00 X 0 0 0 ERIC G WALKER 2.00 X 0 0 0 DANIEL LASTER 2.00 X 0 0 0 THOMAS BREWER 2.00 X 0 0 0 KEITH OLSON 2.00 X 0 0 0 HERBERT MONTGOMERY 2.00 X 0 0 0 MENGHIS BAIRU 2.00 X 0 0 0 NIGEL FLEMING 2.00 X 0 0 0 FRED KYLE 2.00 X 0 0 0 TUE NGUYEN 40.00 X 245879 0 41511 MARIE LENNARTSSON 40.00 X 160673 0 13789 EUGENIO DE HOSTOS 40.00 X 159050 0 33027 RAJ SHANKAR GHOSH 40.00 X 133199 0 22237 NERISSA DEL ROSARIO 40.00 X 131747 0 17147 CAROL YVONNE SIDELL 40.00 X 114200 0 23261 ROBERT CHOY 40.00 X 113656 0 3554 HEALTHER KELLY 40.00 X 110180 0 19058 1964357 0 205730 11 0 1 0 PAUL WILLIAM FINNEGAN 13780 NOB AVENUE DEL MAR CA 92014 LEGAL 233750 MASON S BRUTSCHY 39 LLOYDEN DRIVE ATHERTON CA 94027 FINANCE 214471 CAROL A HILL DBA CLINICON 123 ROSS STREET SANTA CRUZ CA 95060 CLINICAL OPERATIONS 127570 GAIL CHRISTIN CHUN GANNON 503 OSPREY COURT REDWOOD CITY CA 94065 BUSINESS DEVELOPMENT 121500 YUHUA JI 700 FREEPORT LANE REDWOOD CITY CA 94065 CONSULTING 103020 6 15708021 15708021 78945 78945 14986715 14986715 0 0 15786966 0 0 78945 320400 320400 1575000 1575000 1481847 1024408 457439 1719011 747085 910150 61776 25712 25712 614780 328660 266961 19159 173673 101916 65965 5792 43897 32 43139 726 6022875 4733532 1265785 23558 170254 93924 75178 1152 323330 138530 180218 4582 559329 403473 152648 3208 258953 235471 20097 3385 52365 41841 9975 549 48523 12543 35980 COMMUNICATIONS 101837 55377 45144 1316 LICENSES, FEES & SUBSC. 70326 15167 53664 1495 MEDICAL SUPPLIES 62500 62500 CURRENCY FLUCTUATION 20385 -16798 37183 31740 15917 15823 13676737 9888978 3661061 126698 1420827 700953 1054750 2437357 18341 644591 230886 372743 606310 403254 113291 203056 22185000 19926554 1152011 0 40237 0 26215343 24285254 4437688 1581867 4437688 1581867 X 213878 587263 21563777 22116124 21777655 22703387 26215343 24285254 X 2110229 -1184497 X 0 1 1 X 0 X UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER SAN FRANCISCO CA KALA-AZAR MEDICAL RESEARCH CENTRE MAZUFFARPUR IN INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH MOKAKHALI BG RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 194270 95115 99155 379085 275184 103901 32955 32955 0 203056 15786966 13676737 2110229 -32486 -1152011 -1184497 925732 15816382 -32486 96563 64077 15752305 34661 34661 15786966 13738639 96563 96563 13642076 34661 34661 13676737 1 SOUTH ASIA 2 21 MANAGEMENT & GENERAL 504427 SOUTH ASIA 0 0 PROGRAM SERVICES VISCERAL LEISHMANIASIS, DIARRHEAL DISEASE, HELMINTH, ADVOCACY & EX, NEW PROGRAMS 1185926 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 15000 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 1560000 2 21 0 0 2 21 3265353 0 3265353 SOUTH ASIA VACCINES AND IMMUNIZATIONS 15000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) MALARIA 1560000 CHECK 0 2 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: PROGRAMMATIC STAFF WHO WERE INVOLVED WITH THESE SUBS PERFORMED GENERAL REVIEW/MONITORING OF THE SUB ACTIVITIES IN ACCORDANCE WITH SUB-AGREEMENTS. 1 ST LOUIS UNIVERSITY 3545 LINDELL BLVD ST LOUIS MO 63103 430654872 501(C)(3) 235400 DIARRHEAL DISEASE REGENTS OF UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE M/C 0934 SAN DIEGO CA 92093 956006144 501(C)(3) 85000 HELMINTH 2 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: PROGRAMMATIC STAFF WHO WERE INVOLVED WITH THESE SUBS PERFORMED GENERAL REVIEW/MONITORING OF THE SUB ACTIVITIES IN ACCORDANCE WITH SUB-AGREEMENTS. X X 1 1 X X X 1 0 0 0 0 0 0 0 0 RICHARD CHIN 361807 0 75000 0 358966 0 3554 0 28592 0 827919 0 0 0 TUE NGUYEN 201684 0 44195 0 0 0 0 0 41511 0 287390 0 0 0 MARIE LENNARTSSON 146381 0 14292 0 0 0 4820 0 8969 0 174462 0 0 0 EUGENIO DE HOSTOS 132744 0 26306 0 0 0 4959 0 28068 0 192077 0 0 0 RAJ SHANKAR GHOSH 75465 0 20255 0 37479 0 0 0 22237 0 155436 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE AND TAX INDEMNIFICATION ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. THE ENTITY DID NOT HAVE AN EXPLICIT HOUSING ALLOWANCE POLICY IN 2011. HOWEVER, THE HOUSING ALLOWANCES WERE APPROVED ON AS NEEDED BASIS BY THE CEO. PART I, LINE 4A RICHARD CHIN RECEIVED SEVERANCE IN THE AMOUNT OF $358,966. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS AND REVIEWED BY IOWH'S INTERIM PROGRAM LEADER, INTERIM CHIEF FINANCIAL OFFICER, AND BOARD OF DIRECTORS, AS WELL AS BY PATH'S SENIOR MANAGEMENT AND BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ANNUAL DISCLOSURE OF ANY POTENTIAL CONFLICT OF INTEREST IS REQUIRED OF ALL OFFICERS AND KEY ORGANIZATIONAL MEMBERS. FURTHER, THESE STAFF MEMBERS HAVE A DUTY TO DISCLOSE ANY CONFLICT AT THE TIME OF OCCURRENCE. POTENTIAL CONFLICTS OF INTEREST ARE REFERRED TO THE APPROPRIATE BOARD COMMITTEE FOR REVIEW OF ALL MATERIAL FACTS AND CIRCUMSTANCES. ONLY THE INDEPENDENT MEMBERS OF THE COMMITTEE ARE ALLOWED TO VOTE AND DETERMINE WHAT ACTION MUST BE TAKEN. DECISIONS REGARDING A DIRECTOR WITH A MATERIAL FINANCIAL INTEREST IN A TRANSACTION MUST BE RATIFIED BY THE FULL BOARD. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE IOWH BOARD OF DIRECTORS DETERMINED THE COMPENSATION FOR THE ORGANIZATION'S SENIOR MANAGERS. THE REVIEW INCLUDED BENCHMARKING OF THE SALARIES OF PEER PDP ORGANIZATIONS, WHICH THE BOARD DEEMED APPROPRIATE. THE DELIBERATION AND DECISION WAS DOCUMENTED IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE AND UPON REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -32,486. PRIOR PERIOD ADJUSTMENTS: -1,152,011. TOTAL TO FORM 990, PART XI, LINE 5: -1,184,497.